Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

Purpose: In the MONALEESA-3 Phase III trial of patients with hormone receptor–positive human epidermal growth factor receptor–negative advanced breast cancer, ribociclib plus fulvestrant significantly improved progression-free survival (PFS) and overall survival (OS). Here, we present patient-report...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Peter A. Fasching, J. Thaddeus Beck, Arlene Chan, Michele De Laurentiis, Francisco J. Esteva, Guy Jerusalem, Patrick Neven, Xavier Pivot, Giulia V. Bianchi, Miguel Martin, David Chandiwana, Brad Lanoue, Antonia Ridolfi, Yingbo Wang, Karen Rodriguez Lorenc, Arnd Nusch
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2020-12-01
Serie:	Breast
Soggetti:	Breast cancer Metastatic Patient-reported outcomes Quality of life
Accesso online:	http://www.sciencedirect.com/science/article/pii/S0960977620301867
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!